Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study to Characterize the Effects of CCL2 Inhibition With the Spiegelmer® NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria

NCT01547897 is registered in ClinicalTrials.gov with TME Pharma AG as lead sponsor.

NCT NCT01547897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01547897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study to Characterize the Effects of CCL2 Inhibition With the Spiegelmer® NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
Lead sponsor
TME Pharma AG
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
December 31, 2013
Enrollment
76 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

albuminuria, type 2 diabetes mellitus